Molecular Targets on the Horizon in Non–Small Cell Lung Cancer

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the rationale to target TROP-2 in lung cancer.

Erin Schenk, MD, PhD, discusses the importance of investigating novel targets and pathways in lung cancer.

Edgardo S. Santos, MD, discusses the potential role for CEACAM5- and KEAP1-targeted therapies in non–small cell lung cancer.

Justin Gainor, MD, discusses the potential value of targeting TROP-2 and CEACAM5 in lung cancer.

David R. Gandara, MD, discusses recent developments in HER2-targeted therapies as a treatment for patients with non-small cell lung cancer.